Biotech News

Recursion Appoints Fred Hassan as Chair of the Board

Recursion (RXRX)Recursion2026-11-02 21:05 ESTFDA / regulatory

Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, effective October 31, 2026

Mr. Hassan arrives with a strong track record of more than four decades in the pharmaceutical industry. He has grown global businesses and led teams that brought multiple medicines through development, regulatory approval and commercial launch. As an example, the severely challenged Schering-Plough returned to sales growth, strong cash flow, and expanded the number of new molecular entities in Phase 3 development from three to eight.

Related news

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

RHHBYRoche Holdings AG2026-10-16 05:00 EST

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

RHHBYRoche Holdings AG2026-10-09 05:00 EST

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

RXRXRecursion2026-05-29 20:30 EST

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ALVOAlvotech2026-10-05 08:00 EST

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

MDXGMiMedx2026-09-23 20:01 EST

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

ALVOAlvotech2026-08-31 08:30 EST

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations

ENTXEntera Bio2026-06-22 12:30 EST

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

PHARPharming Group2026-03-24 06:00 EST

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

View all latest news

Recursion

AI-Native Drug Discovery Recursion is a clinical-stage TechBio company using an integrated discovery and development platform to generate medicines across oncology, rare disease, neuroscience and immunology. The Recursion OS combines proprietary multimodal biological and chemical data, purpose-built AI models and experimental...

Recent company news

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

RXRXRecursion2026-11-02 21:25 EST

New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps

RXRXRecursion2026-11-02 21:05 EST

Recursion Appoints Fred Hassan as Chair of the Board

RXRXRecursion2026-10-26 20:05 EST

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

RXRXRecursion2026-10-15 12:45 EST

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Stock data

Close: 3.50 USD
Market cap: 1.92B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States